Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have been given an average rating of “Moderate Buy” by the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $42.75.

Separately, Weiss Ratings upgraded Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 21st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC acquired a new position in shares of Kailera Therapeutics in the third quarter worth $134,000. Profund Advisors LLC acquired a new position in shares of Kailera Therapeutics during the 3rd quarter worth about $216,000. Mirador Capital Partners LP purchased a new position in Kailera Therapeutics in the third quarter valued at approximately $666,000. State Street Corp acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $19,126,000. Finally, Tidal Investments LLC acquired a new stake in shares of Kailera Therapeutics during the second quarter worth about $309,000.

Kailera Therapeutics Stock Down 5.5%

Shares of NASDAQ:KLRA opened at $12.15 on Tuesday. The company’s 50 day simple moving average is $13.19. Kailera Therapeutics has a 1 year low of $9.76 and a 1 year high of $28.23. The stock has a market cap of $1.58 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, analysts forecast that Kailera Therapeutics will post -3.89 earnings per share for the current year.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.